Tenofovir Compassionate Use Program

Gilead has announced a small compassionate access study of tenofovir, a prodrug of PMPA. As with ABT-378, there is limited availability of the drug, so entry criteria are fairly restrictive. Patients must be between 18 and 65, have HIV RNA of at least 10,000 and, in most cases, a CD4 count below 50 cells. Those who have had an active, AIDS-defining opportunistic infection within 90 days and a CD4 count between 50 and 200 cells may also qualify for the program.

For more information, doctors should call (800) 276-0231 weekdays between 8:00 a.m. and 6:00 p.m. (EST).

Back to the GMHC Treatment Issues September/October 1999 contents page.